Literature DB >> 28045667

Statin Adjunctive Therapy for Tuberculosis Treatment.

Jan-Willem C Alffenaar1, Onno W Akkerman2,3, Rob van Hest4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28045667      PMCID： PMC5075134          DOI： 10.1128/AAC.01836-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Statin adjunctive therapy shortens the duration of TB treatment in mice.

Authors:  Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2016-02-21       Impact factor: 5.790

Review 2.  Is There Potential for Repurposing Statins as Novel Antimicrobials?

Authors:  Emma Hennessy; Claire Adams; F Jerry Reen; Fergal O'Gara
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.

Authors:  C Kyrklund; J T Backman; K T Kivistö; M Neuvonen; J Laitila; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

4.  Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.

Authors:  Suraj P Parihar; Reto Guler; Rethabile Khutlang; Dirk M Lang; Ramona Hurdayal; Musa M Mhlanga; Harukazu Suzuki; A David Marais; Frank Brombacher
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

Review 5.  New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

Authors:  Alimuddin I Zumla; Stephen H Gillespie; Michael Hoelscher; Patrick P J Philips; Stewart T Cole; Ibrahim Abubakar; Timothy D McHugh; Marco Schito; Markus Maeurer; Andrew J Nunn
Journal:  Lancet Infect Dis       Date:  2014-04       Impact factor: 25.071

6.  Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa.

Authors:  Karen Shean; Elizabeth Streicher; Elize Pieterson; Greg Symons; Richard van Zyl Smit; Grant Theron; Rannakoe Lehloenya; Xavier Padanilam; Paul Wilcox; Tommie C Victor; Paul van Helden; Martin P Grobusch; Martin Groubusch; Robin Warren; Motasim Badri; Keertan Dheda
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

7.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240
  7 in total
  2 in total

1.  Association between Tuberculosis, Statin Use, and Diabetes: A Propensity Score-Matched Analysis.

Authors:  Min-Chul Kim; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

2.  Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.

Authors:  Noton K Dutta; Natalie Bruiners; Matthew D Zimmerman; Shumin Tan; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.